Journal of Oncology Pharmacy Practice

OCT 24, 2026 · JOURNAL ARTICLE

Bispecific T-cell engagers beyond hematology: Expanding uses in solid tumors

Journal of Oncology Pharmacy Practice

Objective To review the mechanism of action, clinical efficacy, safety considerations and future development of bispecific T-cell engagers (BTCEs) in solid tumors. Data sources A l

OCT 15, 2026 · JOURNAL ARTICLE

Medication safety in pediatric oncology survivorship: Polypharmacy, high-risk medications, drug interactions, adherence, and caregiver education

Journal of Oncology Pharmacy Practice

Objective Medication safety is an underdeveloped dimension of pediatric oncology survivorship despite persistent medication exposure after cancer therapy. This review synthesizes e

OCT 9, 2026 · JOURNAL ARTICLE

Tebentafusp desensitization in an adult with metastatic uveal melanoma

Journal of Oncology Pharmacy Practice

IntroductionMetastasis occurs in almost 50% of patients with uveal melanoma. In patients who are HLA-A*02:01 positive, first line treatment is the Immune mobilizing monoclonal T ce

SEP 25, 2026 · JOURNAL ARTICLE

Feasibility and safety of 30-minute Trastuzumab reloading infusion in patients with HER2-positive solid tumors

Journal of Oncology Pharmacy Practice

Introduction Trastuzumab is a humanized HER2 targeting monoclonal antibody, and it is indicated for the treatment of various HER-2-positive cancers, including breast and gastrointe

SEP 22, 2026 · REVIEW

The association of adverse drug reactions with medication adherence among patients with breast cancer: A systematic review and meta-analysis

Journal of Oncology Pharmacy Practice

Introduction This study aimed to systematically evaluate the association between adverse drug reactions, medication adherence, and outpatient treatment outcomes among women with br

SEP 22, 2026 · JOURNAL ARTICLE

AI-Driven precision targeted therapy for EGFR-mutant non-small cell lung cancer: From therapeutic evolution and resistance mechanisms to intelligent decision systems

Journal of Oncology Pharmacy Practice

Objective To critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clin

AUG 18, 2026 · JOURNAL ARTICLE

Effect of BMI on efficacy of androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer

Journal of Oncology Pharmacy Practice

Retrospective cohort study of 330 patients reporting an obesity paradox in mHSPC; confirms known associations but BMI did not retain independent significance in multivariate analysis, limiting practice implications.

AUG 17, 2026 · REVIEW

Efficacy and safety of carboplatin-containing chemotherapy in triple-negative breast cancer: A comprehensive systematic review, meta-analysis, and trial sequential analysis with BRCA/HRD subgroup assessment

Journal of Oncology Pharmacy Practice

High-quality meta-analysis of 23 Phase II/III RCTs (n=8797) demonstrating clinically meaningful improvements in DFS, OS, and pCR with carboplatin-containing chemotherapy in TNBC, with rigorous pooling and quantified safety trade-offs.